icnst-2018-keynote

2 / 5

Page 10
Notes:
alliedacademies
Materials Science and Nanotechnology | Volume 2
May 21-22, 2018 | New York, USA
International Conference on
Nanoscience & Technology
Tumor therapy, especially in the case of multidrug resistant
cancers, could be significantly enhanced by using siRNA
down-regulating the production of proteins, which are involved
in cancer cell resistance, such as Pgp or survivin. Even better
response could be achieved is such siRNA could be delivered
to tumors together with chemotherapeutic agent. This task is
complicated by low stability of siRNA in biological surrounding.
Thus, the delivery system should simultaneously protect
siRNA from degradation. We have developed several types
of lipid-core polymeric micelles based on PEG-phospholipid
or PEI-phospholipid conjugates, which are biologically inert,
demonstrate prolonged circulation in the blood and can firmly
bind non-modified or reversibly-modified siRNA. Additionally,
these nanopreparations can be loaded into their lipidic core
with poorly water soluble chemotherapeutic agents, such
as paclitaxel or camptothecin. In experiments with cancer
cell monolayers, cancer cell 3D spheroids, and in animals
with implanted tumors, it was shown that such co-loaded
preparations can significantly down-regulate target proteins
in cancer cells, enhance drug activity, and reverse multidrug
resistance. Inorder to specificallyunload suchnanopreparations
inside tumors, we made them sensitive to local tumor-specific
stimuli, such as lowered pH, hypoxia, or overexpressed certain
enzymes, such as matrix metalloproteases. Using pH-, hypoxia-,
or MMP2-sensitive bonds between different components of
nanopreparations co-loaded with siRNA and drugs, we were
able to make the systems specifically delivering biologically
active agents in tumors, which resulted in significantly improved
therapeutic response.
Speaker Biography
Vladimir P Torchilin, Ph.D., is a University Distinguished Professor of
Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and
Nanomedicine, Northeastern University, Boston. His interests include drug delivery
and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical
nanocarriers, biomedical polymers, experimental cancer therapy. He has published
more than 400 original papers, more than 150 reviews and book chapters, wrote and
edited 12 books, and hold more than 40 patents. Google Scholar shows more than
52,000 citations of his papers with H-index of 102. He is Editor-in-Chief of Current
Drug Discovery Technologies, Drug Delivery, and Open Nano, Co-Editor of Current
Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He
received more than $30 M from the governmental and industrial sources in research
funding. He has multiple honors and awards and in 2011, Times Higher Education
ranked him number 2 among top world scientists in pharmacology for the period of
2000-2010.
e:
Vladimir P Torchilin
Northeastern University, USA
Multifunctional stimuli-sensitive combination nanopreparations for cancer